Kajetan Kiełbowski, Estera Bakinowska, Przemysław Dymek, Sandra Sienkiewicz, Tomasz Błaszkowski, Maciej Romanowski
{"title":"免疫疗法和其他抗癌药物在晚期胃癌治疗中的应用","authors":"Kajetan Kiełbowski, Estera Bakinowska, Przemysław Dymek, Sandra Sienkiewicz, Tomasz Błaszkowski, Maciej Romanowski","doi":"10.5603/njo.a2022.0043","DOIUrl":null,"url":null,"abstract":"Advanced gastric cancer (AGC) is characterized by high mortality. The survival is estimated as 14.2 months. The treatment of choice in the early stages of GC is surgery. Due to high potential of malignancy, postoperative chemotherapy is usually administered. Novel methods of treatment involve immunotherapeutic agents (IA). The new therapies seem to be a hopeful perspective for patients with advanced GC. In this review, we present the outcomes of clinical trials in GC treatment with IA and their mechanisms of action. Furthermore, we present the benefits and shortcomings of immunotherapy and describe potential directions for future research.","PeriodicalId":130080,"journal":{"name":"Nowotwory. Journal of Oncology","volume":"53 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapeutics and other anticancer agents in the management of advanced gastric cancer\",\"authors\":\"Kajetan Kiełbowski, Estera Bakinowska, Przemysław Dymek, Sandra Sienkiewicz, Tomasz Błaszkowski, Maciej Romanowski\",\"doi\":\"10.5603/njo.a2022.0043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advanced gastric cancer (AGC) is characterized by high mortality. The survival is estimated as 14.2 months. The treatment of choice in the early stages of GC is surgery. Due to high potential of malignancy, postoperative chemotherapy is usually administered. Novel methods of treatment involve immunotherapeutic agents (IA). The new therapies seem to be a hopeful perspective for patients with advanced GC. In this review, we present the outcomes of clinical trials in GC treatment with IA and their mechanisms of action. Furthermore, we present the benefits and shortcomings of immunotherapy and describe potential directions for future research.\",\"PeriodicalId\":130080,\"journal\":{\"name\":\"Nowotwory. Journal of Oncology\",\"volume\":\"53 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nowotwory. Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/njo.a2022.0043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory. Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/njo.a2022.0043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Immunotherapeutics and other anticancer agents in the management of advanced gastric cancer
Advanced gastric cancer (AGC) is characterized by high mortality. The survival is estimated as 14.2 months. The treatment of choice in the early stages of GC is surgery. Due to high potential of malignancy, postoperative chemotherapy is usually administered. Novel methods of treatment involve immunotherapeutic agents (IA). The new therapies seem to be a hopeful perspective for patients with advanced GC. In this review, we present the outcomes of clinical trials in GC treatment with IA and their mechanisms of action. Furthermore, we present the benefits and shortcomings of immunotherapy and describe potential directions for future research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
